• Have signed the ICF;

• Be able to follow the requirements of study protocol;

• Age ≥18 years;

• Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 to 2;

• Cohort 1: Patients with R/R primary AML harboring IDH1-R132 site mutation \[WHO 2022 Classification Criteria for Myeloid Neoplasms and Acute Leukemia, with the exception of APL (AML-M3) and extramedullary recurrence of leukemia alone without bone marrow involvement\]; Cohort 2: Patients with R/R primary AML harboring IDH2-R140/R172 mutations \[WHO 2022 Classification Criteria for Myeloid Neoplasms and Acute Leukemia, with the exception of APL (AML-M3) and recurrence of extramedullary leukemia alone without bone marrow involvement\]. A patient with both IDH1 and IDH2 mutations will be included in Cohort 2 (IDH2 mutation group);

• Agree to undergo bone marrow aspiration and/or biopsy before and during treatment;

• Be willing to complete QoL assessments at specified time points during study treatment and after treatment discontinuation;

• Female patients of childbearing potential must agree to use highly effective contraceptive methods during the study and within 30 days after discontinuation of the study drug (the time limit of contraception for the chemotherapy group needs to be extended to 6 months after the last dose) (see Appendix 9 (contraception requirements) for more information), and agree not to donate eggs (oocytes) for reproductive purposes during this period; patients must not be lactating and must have a negative pregnancy test (if of childbearing potential);

• Male patients with female partners of childbearing potential must use condoms during intercourse and avoid donating or freezing sperm during the study and within 30 days after discontinuation of the study drug (the time limit of contraception for the chemotherapy group needs to be extended to 6 months after the last dose).

⁃ Predicted survival greater than 12 weeks as assessed by the investigator.